Ipsen


Ipsen is a French pharmaceutical company headquartered in Paris, France.
It develops and markets medications used in oncology, neuroscience and rare diseases along with consumer healthcare products.
It is publicly traded on the Euronext Paris as part of the SBF 120 index.
Ipsen, founded by Henri Beaufour in 1929, has more than 5,800 employees worldwide, marketing over 20 drugs in 115 countries.

Overview

Ipsen is a global specialty-driven pharmaceutical company with total sales exceeding €2.56 billion in 2019.
The Beaufour family, which ranks as the 42nd richest family in France, still owns 57% of its shares and 73% of its voting rights, and two of its members, Anne Beaufour and Henri Beaufour, sit on its board of directors.
In 2019, Ipsen spent close to €388.8 million—15.1% of consolidated sales—on research and development.
In February 2015, the company announced it would Canbex Therapeutics $6.8 million upfront upon completion of a Phase IIA study of Canbex's lead multiple sclerosis compound, VSN16R.
in October 2016, European Commission approves Ipsen's Cabometyx Tablets for the treatment of advanced renal cell carcinoma in adults following prior vascular endothelial growth factor -targeted therapy.
The CABOSUN study, presented at the European Society for Medical Oncology 2016 congress, showed Cabometyx can decrease the rate of disease progression or death by 31% in advanced renal cell carcinoma.
In November 2018, the European Commission approved Cabometyx 20, 40, 60 mg as a monotherapy for hepatocellular carcinoma in adults who have previously been treated with sorafenib. This approval allows for the marketing of Cabometyx in this indication in all 28 member states of the European Union, Norway and Iceland.
In February 2019, Ipsen announced it would acquire Clementia Pharmaceuticals, a biopharmaceutical company specialized in rare bone diseases, for $1.3 billion. This acquisition is the largest in the history of Ipsen. In April 2019, Ipsen announced the deal was finalized.

Research and development

In 2019, Ipsen's R&D expenditure totaled close to €388.8 million, representing more than 15.1% of group sales.
Ipsen's main research and development centers are located in Cambridge, Milton Park / Oxford and Paris Saclay.

Governance

Board of directors

The board of directors sets the strategic guidelines for Ipsen's activities and oversees implementation.
Corporate executives are responsible for managing the group's operations and coordinating the group's various scientific, legal, financial, commercial and strategic actions.
In 1983, Ipsen founded the Ipsen Foundation with the help of the Fondation de France to track progress in biomedical research. It is headquartered in Boulogne-Billancourt. It has organised 64 colloquia, and it has partnered with the World Health Organization, the Fondation Nationale de Gérontologie, Harvard University, the Salk Institute for Biological Studies, the Massachusetts General Hospital, and the academic journals Nature and Cell.